帕利哌酮缓释片联合认知疗法治疗首发精神分裂症的临床疗效分析

Clinical efficacy of paliperidone extended-release tablets combined with cognitive therapy in the treatment of first-onset schizophrenia

目的探究首发精神分裂症应用帕利哌酮缓释片联合认知疗法治疗的效果。方法84例首发精神分裂症患者,按照简单数字表法分为实验组和对照组,各42例。对照组施行帕利哌酮缓释片治疗,实验组施行帕利哌酮缓释片联合认知疗法治疗。比较两组患者治疗3个月末临床缓解率及1年末复发率,治疗3个月后阳性与阴性症状量表(PANSS)评分,治疗3个月后个人与社会表现量表(PSP)评分。结果实验组治疗3个月末临床缓解率95.24%高于对照组的73.81%,1年末复发率2.38%低于对照组的19.05%,差异有统计学意义(P<0.05)。治疗3个月后,观察组患者阴性症状评分(5.3±4.9)分、一般病理症状评分(11.5±3.5)分及总分(33.0±11.2)分均明显低于对照组的(8.3±5.1)、(16.1±4.3)、(40.7±10.5)分,差异具有统计学意义(P<0.05);但两组阳性症状评分比较差异无统计学意义(P>0.05)。治疗3个月后,实验组PSP评分为(55.67±4.32)分,高于对照组的(47.89±4.36)分,差异具有统计学意义(t=8.215,P=0.000<0.05)。结论首发精神分裂症应用帕利哌酮缓释片联合认知疗法治疗可提高临床缓解率,降低复发率,可改善患者相关个人和社会功能指标,可在临床推广。

Objective To investigate the effect of paliperidone extended-release tablets combined with cognitive therapy in the treatment of first-onset schizophrenia.Methods A total of 84 patients with first-onset schizophrenia were divided into experimental group and control group according to the simple number table,with 42 cases in each group.The control group was treated with paliperidone extended-release tablets,and the experimental group was treated with paliperidone extended-release tablets and cognitive therapy.Comparison was made on clinical remission rate after 3 months of treatment,recurrence rate after 1-year follow-up,positive and negative symptom scale(PANSS)score and personal and social performance scale(PSP)score after 3 months of treatment between the two groups.Results The clinical remission rate after 3 months of treatment was 95.24%in the experimental group,which was higher than 73.81%in the control group;the recurrence rate after 1-year followup was 2.38%in the experimental group,which was lower than 19.05%in the control group;all the differences were statistically significant(P<0.05).After 3 months of treatment,the negative symptom score(5.3±4.9)points,general pathological symptom score(11.5±3.5)points and total score(33.0±11.2)points of the observation group were significantly lower than(8.3±5.1),(16.1±4.3),(40.7±10.5)points of the control group,and the difference was statistically significant(P<0.05).However,there was no statistically significant difference in positive symptom score between the two groups(P>0.05).After 3 months of treatment,the PSP score of the experimental group was(55.67±4.32)points,which was higher than(47.89±4.36)points of the control group,and the difference was statistically significant(t=8.215,P=0.000<0.05).Conclusion The treatment of first-onset schizophrenia with paliperidone extended-release tablets and cognitive therapy can increase the clinical remission rate,reduce the recurrence rate,and improve related cognitive function indicators.This method can be promoted clinically.